

March 27, 2014
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Announcement Personnel Changes

TOKYO, Japan, March 27, 2014 - Symbio Pharmaceuticals Limited today announced that it has appointed Mr. Takihiko Hirasawa as Chief Financial Officer and Chief Business Officer effective April 1, 2014, to further strengthen the company's overall management and enhance operational capabilities. Mr. Hirasawa brings to Symbio a wealth of management and business development experience. In particular, his business experience and expertise in building and expanding business internationally will prove to be invaluable as Symbio continues to build its business not only in Japan, but in other key Asia Pacific markets.

Mr. Hirasawa has spent 27 years working for Eisai Co., Ltd. where he gained invaluable experience in various facets of the pharmaceutical business encompassing the clinical development of drugs in oncology and other therapeutic areas, product strategy and business development. While serving as Director of Corporate Planning at Eisai Europe Limited based in the UK, he took a strong initiative as a member of the leadership team in the establishment of the Eisai Knowledge Centre. He played an important role in developing the company's European-wide business strategy and expanding its sales network in the region. He later served as President of Eisai Limited, the company's pharmaceutical sales subsidiary in Canada, where he was responsible for starting up operations, building the company and its management team, and was successful in expanding Eisai's sales capabilities with regulatory approvals for 5 NDAs and launch of 4 products in Canada.

Mr. Hirasawa earned his MBA from Kellogg Business School at Northwestern University (1998), and B.Sc. in Pharmacy from Gifu Pharmaceutical University in Japan (1987).

[Contact]

Investor Relations, Corporate Planning Department

Tel: +081(0)3 5472 1125